Benlysta (belimumab) / GSK - LARVOL DELTA

Updates on the Evaluation of Lupus Arthritis. (PubMed, Rheumatol Ther) - "Therapeutically, hydroxychloroquine (HCQ) remains the foundation of treatment. Belimumab and anifrolumab are US Food and Drug Administration (FDA)-approved biologics now recommended as standard of care for persistent disease, alongside conventional immunosuppressants such as methotrexate, mycophenolate, or azathioprine when indicated. Additional targeted therapies including obinutuzumab and Janus kinase (JAK) inhibitors are closely following behind. Chimeric antigen receptor T cell (CAR-T) represents a promising approach that may transform the future management of SLE."

IO biomarker • Journal • Review • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Musculoskeletal Diseases • Musculoskeletal Pain • Rheumatology • Systemic Lupus Erythematosus • IL17A • IL6

Indirect Treatment Comparison of Belimumab Versus Obinutuzumab in MMF-Treated Patients with Active Proliferative Lupus Nephritis (ACR Convergence 2026) - No abstract available

Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Comparative Efficacy and Safety of Voclosporin, Belimumab, and Obinutuzumab in Lupus Nephritis: A Systematic Review and Network Meta-Analysis of 9 Randomized Controlled Trials (ACR Convergence 2026) - No abstract available

Retrospective data • Review • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Efficacy and Safety of Belimumab, Anifrolumab, and Obinutuzumab for Systemic Lupus Erythematosus: A Network Meta-analysis (ACR Convergence 2026) - No abstract available

Retrospective data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review. (PubMed, Front Immunol) - "We observed that autoantibody-mediated diseases pemphigus vulgaris and myasthenia gravis had the most superior and durable immune response to B-cell depletion by rituximab and inebilizumab, respectively...Combination therapy using belimumab and rituximab resulted in a significantly better clinical outcome than monotherapy in Sjögren's syndrome...The success of B-cell therapeutics appears to align with B-cell contribution, disease biology, and the depth of B-cell targeting in autoimmune conditions. Precision targeting is needed to effectively combat autoimmune diseases."

Journal • Review • CNS Disorders • Dermatology • Immunology • Inflammatory Arthritis • Myasthenia Gravis • Pemphigus Vulgaris • Rheumatoid Arthritis • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis

B-cell-targeted therapy for systemic lupus erythematosus-associated warm autoimmune haemolytic anaemia: a real-world comparative cohort study. (PubMed, Rheumatology (Oxford)) - "Six- and 12-month ORR did not differ significantly between treatment strategies. The numerically higher complete response rate, more stable 12-month response and earlier glucocorticoid reduction with B-cell-targeted therapy, together with the telitacicept findings, are exploratory and require prospective validation."

Journal • Real-world evidence • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Dangerous MASquerade: Severe Acute Pancreatitis Associated With Macrophage Activation Syndrome (ACG 2026) - "Case Description/ A 43-year-old man with rheumatoid arthritis on adalimumab was admitted for malaise, cough, and fever...Pulse methylprednisolone was administered as well as cyclophosphamide and belimumab...Figure: Figure 2. Follow-up computed tomography of the abdomen and pelvis demonstrating complex loculated ascites with peritoneal thickening, retroperitoneal edema, and omental inflammation, reflecting progressive serositis."

Cardiovascular • Cough • Dermatitis • Endocrine Disorders • Glomerulonephritis • Heart Failure • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pancreatitis • Rare Diseases • Respiratory Diseases • Rheumatoid Arthritis • Systemic Lupus Erythematosus • IL2

A Rare Case of Dysphagia Secondary to Primary Esophageal Brown Bowel Syndrome (ACG 2026) - "Case Description/ A 47-year-old female with systemic lupus erythematosus (SLE) on belimumab and a complex bariatric history (Roux-en-Y gastric bypass, then stomach intestinal pylorus sparing surgery, then conversion to biliopancreatic diversion with duodenal switch [BPD-DS]) presented with three years of progressive dysphagia...She completed two weeks of IV fluconazole with resolution of candidiasis and improvement in dysphagia...Early recognition through fat-soluble vitamin monitoring and biopsy of non-traditional sites in high-risk patients allows vitamin E repletion prior to irreversible myopathy. Figure: (A) Hematoxylin and Eosin (H&E) stain; (B) Periodic acid-Schiff with diastase (PASD) stain; (C) Fontana-Masson stain highlight lipofuscin granules in the esophageal smooth muscle cells."

Clinical • Candidiasis • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Lupus • Myositis • Systemic Lupus Erythematosus

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: NYU Langone Health | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2027 ➔ Jan 2028 | Initiation date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2027 ➔ Jan 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Orthopedics • Psoriatic Arthritis • Rheumatology

Tofacitinib versus belimumab in maintenance therapy of systemic lupus erythematosus: A real-world CSTAR cohort study. (PubMed, Chin Med J (Engl)) - No abstract available

Journal • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Treatment-driven peripheral blood transcriptomic remodelling and baseline predictors of ESSDAI and STAR response to B-cell therapy in Sjögren's disease. (PubMed, Arthritis Rheumatol) - P2 | "The distinct ESSDAI and STAR ligand-receptor signatures indicate different systemic biological drivers of non-response to B-cell therapies in SjD. Their complete non-overlap suggests entrenched B-cell-independent inflammatory circuits, highlighting complement regulation, TGFB2-mediated remodelling, IL-1/IL-18 signalling and FcγR activation as rational treatment pathways beyond B-cell-targeted therapies."

Journal • Sjogren's Syndrome • CD8 • FCGR2A • IL18 • IL1R1 • IL1RAP • SPP1 • STAR • TGFB2 • TLR4

Pathogenic B-T Cell Axis Driven by BAFF Induces Endothelial Apoptosis in SLE-PAH. (PubMed, Circ Res) - "The therapeutic efficacy of the BAFF-neutralizing antibody Belimumab was tested in 2 distinct SLE-PAH animal models...These findings establish BAFF as a key mediator in SLE-PAH, driving a previously unrecognized pathogenic immune axis connecting dysregulated B cells to T-cell-mediated endothelial injury. BAFF inhibition may represent a therapeutic strategy for SLE-PAH."

Journal • Cardiovascular • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Systemic Lupus Erythematosus • CD8 • CD80 • FASLG • GZMK • S100A6

Glucocorticoid tapering and clinical outcomes during belimumab treatment in systemic lupus erythematosus: a retrospective real-world cohort study with exploratory renal analyses. (PubMed, BMC Rheumatol) - "In this real-world cohort, PSL doses decreased during follow-up after the initiation of BEL, while the overall disease activity remained controlled. In the small LN subgroup, the UPCR decreased at 52 weeks, and no statistically significant change in eGFR was detected. Because this study lacked a comparator group and the renal analyses were exploratory and limited by the small sample size, heterogeneous treatment backgrounds, and variable biopsy timing, these findings should be interpreted as within-patient observational data and require validation in future studies."

Clinical data • Journal • Real-world evidence • Retrospective data • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus

Clinical Phenotypes, Disease Activity Outcomes, and Glucocorticoid Use Among Belimumab- and Anifrolumab-Treated Patients With Non-Renal SLE (ACR Convergence 2026) - No abstract available

Clinical • Inflammatory Arthritis

Anifrolumab versus Belimumab for Cardiovascular Disease Risk in Systemic Lupus Erythematosus (ACR Convergence 2026) - No abstract available

Cardiovascular • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Efficacy and Safety of Belimumab without Glucocorticoid Use in Systemic Lupus Erythematosus: A Pilot Randomized Double-Blind Placebo-Controlled Trial (ACR Convergence 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

The Sjögren's Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 17 recent RCTs in Sjögren's disease (ACR Convergence 2026) - P1/2, P2, P2/3, P3 | " The following data were used to assess the performance of 20 STAR candidate options: Data from 9 clinical trials used for STAR development: abatacept (NCT02915159), leflunomide + hydroxychloroquine (REPURPSS-I, EudraCT 2020-001933-11), rituximab (TEARS NCT0074094, TRACTISS ISRCTN65360827), hydroxychloroquine (JOQUER NCT00632866), tocilizumab (NCT01782235), baminercept (NCT01552681), and phase II trials of iscalimab (NCT02291029) and ianalumab (NCT02962895). Data from 7 independent clinical trial datasets (external validation set): belimumab ± rituximab (NCT02631538), abatacept (NCT02915159), anti-IL-7 therapy (NCT04605978), remibrutinib (NCT04035668), iscalimab (NCT03905525, cohorts 1 and 2), leflunomide + hydroxychloroquine (EudraCT 2020-001933-11), and dazodalibep (NCT04129164)... This large number of new trials provided a large amount of data for informing the selection of the final STAR responder index. The STAR 3AV1 where response rely on..."

Clinical • Sjogren's Syndrome • IL7

BE-EARLY: Interim Week 26 Analysis of a Phase 4, Prospective, Open-Label Study Evaluating Belimumab in Early SLE (≤2 Years Since Diagnosis) (ACR Convergence 2026) - No abstract available

Clinical • P4 data • Inflammatory Arthritis

Clinical Outcomes of Early Treatment Initiation with Belimumab in Patients with SLE: Preliminary Results of RELIABLE (ACR Convergence 2026) - No abstract available

Clinical • Clinical data • Inflammatory Arthritis

Low Five Year Mortality in SLE Treated with Belimumab: Findings from the Prospective, Global, SABLE Registry (ACR Convergence 2026) - No abstract available

Clinical • Inflammatory Arthritis

Kidney Function Preservation with Belimumab in Patients with Lupus Nephritis (LN) in Routine Care Settings: Preliminary 24-Month Interim Analysis of the OBSErve-LN Study (ACR Convergence 2026) - No abstract available

Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Incident Lupus Nephritis After Anifrolumab Versus Belimumab in Systemic Lupus Erythematosus: A Propensity-Matched Cohort Study (ACR Convergence 2026) - No abstract available

Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus

Belimumab for Refractory and Non-criteria Manifestations of Primary Antiphospholipid Syndrome: Results from the Prospective Phase II BLAST Trial (ACR Convergence 2026) - No abstract available

Clinical • P2 data • Genetic Disorders • Hematological Disorders

Voclosporin vs. Belimumab in Lupus Nephritis: Two-Year Renal Outcomes in a Retrospective Propensity Score-Matched Real-World Cohort (ACR Convergence 2026) - No abstract available

Real-world • Real-world evidence • Retrospective data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

BE-MOBILYZED: Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: Leiden University Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Transplant Rejection • Transplantation • CD4 • CD52